CA2944610C - (5,6-dihydro)pyrimido[4,5-e]indolizines - Google Patents

(5,6-dihydro)pyrimido[4,5-e]indolizines Download PDF

Info

Publication number
CA2944610C
CA2944610C CA2944610A CA2944610A CA2944610C CA 2944610 C CA2944610 C CA 2944610C CA 2944610 A CA2944610 A CA 2944610A CA 2944610 A CA2944610 A CA 2944610A CA 2944610 C CA2944610 C CA 2944610C
Authority
CA
Canada
Prior art keywords
carboxamide
indolizine
anilino
methoxy
dihydropyrimido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2944610A
Other languages
English (en)
French (fr)
Other versions
CA2944610A1 (en
Inventor
Adrianus Petrus Antonius De Man
Rogier Christian Buijsman
Jan Gerard STERRENBURG
Joost Cornelis Marinus UITDEHAAG
Joeri Johannes Petrus DE WIT
Guido Jenny Rudolf Zaman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Netherlands Translational Research Center BV
Original Assignee
Netherlands Translational Research Center BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Translational Research Center BV filed Critical Netherlands Translational Research Center BV
Publication of CA2944610A1 publication Critical patent/CA2944610A1/en
Application granted granted Critical
Publication of CA2944610C publication Critical patent/CA2944610C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2944610A 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines Active CA2944610C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14163734.8 2014-04-07
EP14163734 2014-04-07
EP15153207 2015-01-30
EP15153207.4 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (2)

Publication Number Publication Date
CA2944610A1 CA2944610A1 (en) 2015-10-15
CA2944610C true CA2944610C (en) 2024-01-09

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2944610A Active CA2944610C (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Country Status (16)

Country Link
US (3) US9856258B2 (https=)
EP (1) EP3129374B1 (https=)
JP (1) JP6518690B2 (https=)
KR (1) KR102432420B1 (https=)
CN (1) CN106132963B (https=)
AU (1) AU2015243694B2 (https=)
BR (1) BR112016022342B1 (https=)
CA (1) CA2944610C (https=)
DK (1) DK3129374T3 (https=)
ES (1) ES2716165T3 (https=)
HU (1) HUE043108T2 (https=)
MX (1) MX368767B (https=)
PL (1) PL3129374T3 (https=)
PT (1) PT3129374T (https=)
RU (1) RU2692479C2 (https=)
WO (1) WO2015155042A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856258B2 (en) * 2014-04-07 2018-01-02 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-E]indolizines
FI3283642T3 (fi) 2015-04-17 2024-01-11 Crossfire Oncology Holding B V Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan
DK3416964T3 (da) * 2016-02-19 2021-02-22 Phoenix Molecular Designs 6-Oxo-N-(1-(benzyl)-1H-pyrazol-4-YL)-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[1,2-A]pyrazin-2-carboxamid-derivater som P90 ribosomal S6 kinase- (RSK-) hæmmere til behandling af cancer
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
KR20240026521A (ko) 2017-03-23 2024-02-28 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
US12378245B2 (en) 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
AU2022408915A1 (en) * 2021-12-15 2024-06-27 Sillajen, Inc. Methods of treating neoplastic diseases
KR20240107189A (ko) * 2021-12-15 2024-07-08 신라젠(주) 신생물성 질환 치료에 사용하기 위한 약제학적 병용물
MX2024007452A (es) * 2021-12-15 2024-07-09 Sillajen Inc Composiciones farmaceuticas que comprenden beta-ciclodextrinas modificadas.
WO2023167549A1 (en) * 2022-03-04 2023-09-07 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160915A0 (en) * 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
PT1636236E (pt) 2003-05-22 2013-12-16 Nerviano Medical Sciences Srl Derivados de pirazol-quinazolina, processo para sua preparação e sua utilização como inibidores de cinase
EP2118102B1 (en) 2006-11-28 2013-06-12 Nerviano Medical Sciences S.r.l. Tricyclic indoles and (4,5-dihydro) indoles
MX2010013843A (es) 2008-06-26 2011-01-21 Nerviano Medical Sciences Srl Pirazolo-quinazolinas.
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
EP2424868B1 (en) 2009-04-29 2018-01-10 Nerviano Medical Sciences S.r.l. Cdk inhibitor salts
JP5851990B2 (ja) 2009-07-29 2016-02-03 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｐｌｋ阻害剤の塩
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
CN103415518A (zh) * 2010-12-17 2013-11-27 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪
ES2602791T3 (es) * 2011-01-26 2017-02-22 Nerviano Medical Sciences S.R.L. Derivados de pirrolo tricíclicos, proceso para su preparación y su uso como inhibidores de cinasa
JP6523267B2 (ja) 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用
US9856258B2 (en) * 2014-04-07 2018-01-02 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-E]indolizines

Also Published As

Publication number Publication date
US9856258B2 (en) 2018-01-02
EP3129374B1 (en) 2018-12-19
JP2017510595A (ja) 2017-04-13
RU2016141405A (ru) 2018-05-07
BR112016022342B1 (pt) 2022-10-04
CN106132963B (zh) 2019-08-06
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
RU2692479C2 (ru) 2019-06-25
EP3129374A1 (en) 2017-02-15
BR112016022342A8 (pt) 2021-07-20
JP6518690B2 (ja) 2019-05-22
MX368767B (es) 2019-10-15
PL3129374T3 (pl) 2019-07-31
HUE043108T2 (hu) 2019-07-29
KR102432420B1 (ko) 2022-08-17
PT3129374T (pt) 2019-03-25
CA2944610A1 (en) 2015-10-15
AU2015243694B2 (en) 2019-01-17
CN106132963A (zh) 2016-11-16
BR112016022342A2 (pt) 2017-08-15
USRE48974E1 (en) 2022-03-15
ES2716165T3 (es) 2019-06-10
MX2016012997A (es) 2016-12-07
USRE50082E1 (en) 2024-08-20
RU2016141405A3 (https=) 2018-10-02
DK3129374T3 (en) 2019-04-08
KR20170013866A (ko) 2017-02-07
AU2015243694A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
CA2944610C (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
CN112094269B (zh) 一类饱和六元环并杂环类化合物、制备方法和用途
ES2904544T3 (es) Compuestos de indazol como inhibidores de la cinasa FGFR, preparación y uso de los mismos
EP3559000B1 (en) Benzimidazole derivatives, preparation methods and uses theirof
EP3173412B1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
EP3621968A1 (en) Heteroaryl compounds that inhibit g12c mutant ras proteins
CA3099315A1 (en) Erbb receptor inhibitors
CN107613769A (zh) 某些化学实体、组合物和方法
JP2018507883A (ja) 抗がん剤としての置換２−ｈ−ピラゾール誘導体
AU2020255100A1 (en) N-heteroaromatic amide derivatives for treatment of cancer
AU2013344049A1 (en) ALK kinase inhibitors
AU2015407300A1 (en) 2-Arylamino pyridine, pyridine or triazine derivative, preparation method and use thereof
WO2014100540A1 (en) Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
CA2982862A1 (en) Preparation and use of kinase inhibitor
KR20250159187A (ko) Cdk12/13에 대한 아릴 치환기 함유 분해제, 이의 제조 방법, 및 이의 약제학적 조성물과 용도
CN113880814B (zh) 一种嘧啶胺类化合物及应用
CN115348963B (zh) 吡啶并嘧啶类化合物及其应用
RU2605400C1 (ru) ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2
HK1231072A1 (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
HK1231072B (zh) (5，6-二氢)嘧啶并[4，5-e]吲嗪
HK40001081A (en) Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200329

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250210

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250210

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20250625

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20250625

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250702

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250723

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250723

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260324